We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
276
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-533
Closed -$620K
MRTX
277
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-12,213
Closed -$203K
PRTK
278
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-23,444
Closed -$945K
INFI
279
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-508
Closed -$702K
INFI
280
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-70,000
Closed -$967K
SRNE
281
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-222,026
Closed -$1.8M
TWTR
282
DELISTED
Twitter, Inc.
TWTR
– –
-72,300
Closed -$4.6M
TWTR
283
PUT
DELISTED
Twitter, Inc.
TWTR
– –
-62
Closed -$395K
HSTO
284
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-529
Closed -$683K
ARNA
285
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-918
Closed -$5.37M
ALXN
286
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-389
Closed -$5.18M
STML
287
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-68,100
Closed -$1.33M
ACHN
288
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-453,380
Closed -$1.59M
WCG
289
CALL
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-2,082
Closed -$14.7M
WCG
290
PUT
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-40
Closed -$282K
FCSC
291
DELISTED
Fibrocell Science Inc.
FCSC
– –
-5,967
Closed -$363K
ECYT
292
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-55,849
Closed -$810K
KERX
293
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-10,147
Closed -$13.1M
CASC
294
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-119,667
Closed -$1.96M
SGYPW
295
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
– –
-349,217
Closed -$751K
AEGR
296
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-1,375
Closed -$9.76M
AEGR
297
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-1,820
Closed -$12.9M
SQNM
298
CALL
DELISTED
SEQUENOM INC NEW
SQNM
– –
-293
Closed -$69K
SQNM
299
DELISTED
SEQUENOM INC NEW
SQNM
– –
-20,500
Closed -$48K
SQNM
300
PUT
DELISTED
SEQUENOM INC NEW
SQNM
– –
-205
Closed -$48K
9 10 11
12
13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.